The long-term trend of the EPS is an important number as it indicates the present value of Ionis Pharmaceuticals. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 6.10 % over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money Ionis Pharmaceuticals is making for it’s investors or shareholders.

Ionis Pharmaceuticals is in the healthcare sector and is in the biotechnology industry. The company CEO is Stanley T. Crooke. Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.

Previous Intraday Performance:

The IONS shares had a previous change of -5.95% which opened at 59.40 and closed at 56.00. It moved to an intraday high of 59.75 and a low of 55.82.

SeekingAlpha:  FDA accepts Novartis’ marketing application for SMA Type 1 gene therapy AVXS-101

Historical Performance:

Over the last five trading days, IONS shares returned -3.38% and in the past 30 trading days it returned 14.66%. Over three months, it changed 4.28%. In one year it has changed 6.71% and within that year its 52-week high was 59.81 and its 52-week low was 39.07. IONS stock is 43.33% above its 52 Week Low.

Our calculations result in a 200 day moving average of 47.45 and a 50 day moving average of 50.48. Right now, IONS stock is trading 18.01% above its 200 day moving average.

SeekingAlpha:  FDA accepts Novartis’ marketing application for SMA Type 1 gene therapy AVXS-101


The company has a market cap of $7.7b with 137.6m shares outstanding and a float of 137.0m shares. Trading volume was 1,454,021 shares and has experienced an average volume of 1,075,462 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.


The last annual reported EPS for Ionis Pharmaceuticals was -0.02 which ended on 31st of December 2017. Based on 6 analyst estimates, the consensus EPS for the next quarter is -0.13.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.03
06-30-2018:  -0.05
03-31-2018:  -0.01
12-31-2017:  0.02

Base on our calculations, the intrinsic value per share is 41.13, which means it might overvalued by -36.16%

Indicators Also to Watch:

Based on the latest filings, there is 148.20% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be 2.38

PR Newswire:  Inspired Announces Virtual Sports Launch With Danske Spil

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -9.78%, return on assets is -2.85%, profit margin is -43.35%, price-to-sales is 34.33 and price-to-book is 9.26.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here